Dennis Cho Sells 1,507 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 1,507 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $72,336.00. Following the completion of the transaction, the insider now owns 91,163 shares in the company, valued at approximately $4,375,824. This represents a 1.63 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Dennis Cho also recently made the following trade(s):

• On Monday, November 4th, Dennis Cho sold 659 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total transaction of $27,388.04.
• On Wednesday, October 2nd, Dennis Cho sold 3,104 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total transaction of $134,123.84.
• On Friday, September 20th, Dennis Cho sold 234 shares of Twist Bioscience stock. The shares were sold at an average price of $46.94, for a total transaction of $10,983.96.

Twist Bioscience Stock Down 8.3 %

NASDAQ:TWST opened at $38.96 on Friday. The stock’s 50-day simple moving average is $43.90 and its 200 day simple moving average is $45.88. Twist Bioscience Co. has a 52-week low of $18.80 and a 52-week high of $60.90.

Institutional Investors Weigh In On Twist Bioscience

Several large investors have recently made changes to their positions in the stock. American International Group Inc. raised its holdings in shares of Twist Bioscience by 0.8% in the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock valued at $978,000 after purchasing an additional 213 shares during the period. Caprock Group LLC grew its holdings in Twist Bioscience by 2.9% during the second quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock worth $387,000 after purchasing an additional 220 shares during the period. Signaturefd LLC increased its holdings in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares during the last quarter. Arizona State Retirement System raised its stake in Twist Bioscience by 1.9% in the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after acquiring an additional 308 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its holdings in Twist Bioscience by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock valued at $457,000 after purchasing an additional 312 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on TWST shares. Barclays cut their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Evercore ISI increased their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Leerink Partners upped their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Finally, JPMorgan Chase & Co. upped their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.